<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="pediatricmusic/PMC6918555/results/search/drugs/results.xml">
  <result pre="current body of evidence, including safety issues. In this perspective," exact="omalizumab" post="-an anti-IgE monoclonal antibody-, alone or combined with oral"/>
  <result pre="Dawson P, et al. A randomized, double-blind, placebo-controlled study of" exact="omalizumab" post="combined with oral immunotherapy for the treatment of cow's"/>
  <result pre="Mennini M, Pecora V, Fierro V, et al. Impact of" exact="omalizumab" post="on food allergy in patients treated for asthma: a"/>
  <result pre="trial in sJIA, MAS was observed in some patients receiving" exact="tocilizumab" post="[2-3]. High serum levels of IL-18 have been observed"/>
  <result pre="aggregation test showed severe defect in response to ADP, collagen," exact="epinephrine" post="and reduced to ristocetin. Further evaluation showed total GpIIb"/>
  <result pre="syndrome and pulmonary disorders, spleen sequestration and splenectomy, transfusion and" exact="hydroxyurea" post="therapy were some of the most relevant issues addressed"/>
  <result pre="at high risk of this life-threatening complication [5] and on" exact="hydroxyurea" post="therapy in SCD children [6]. Acknowledgements We thank SITE"/>
  <result pre="indicators: the total antibiotic prescription rate and the ratio of" exact="amoxicillin" post="versus amoxicillin-clavulanic acid. Throughout the project, papers both in"/>
  <result pre="children), along with a relative growth of the use of" exact="amoxicillin" post="(the ratio of amoxicillin to amoxicillin-clavulanic acid increased from"/>
  <result pre="relative growth of the use of amoxicillin (the ratio of" exact="amoxicillin" post="to amoxicillin-clavulanic acid increased from 0.6 to 1.3 in"/>
  <result pre="(quite higher than the one in Emilia-Romagna), and ratio of" exact="amoxicillin" post="to amoxicillin-clavulanic acid 0.3 (much lower than the one"/>
  <result pre="antibiotic prophylaxis; the promising results reported with the CXCR4 antagonist" exact="plerixafor" post="[8] paved the way to the future treatment of"/>
  <result pre="(43%) no germ was isolated. The most used antibiotics were" exact="ceftriaxone" post="(36 %), rifampicin (36 %), meropenem (29 %), linezolid"/>
  <result pre="was isolated. The most used antibiotics were ceftriaxone (36 %)," exact="rifampicin" post="(36 %), meropenem (29 %), linezolid (21%), amoxicillin (14%)"/>
  <result pre="most used antibiotics were ceftriaxone (36 %), rifampicin (36 %)," exact="meropenem" post="(29 %), linezolid (21%), amoxicillin (14%) and vancomycin (14"/>
  <result pre="were ceftriaxone (36 %), rifampicin (36 %), meropenem (29 %)," exact="linezolid" post="(21%), amoxicillin (14%) and vancomycin (14 %). Ciprofloxacin was"/>
  <result pre="(36 %), rifampicin (36 %), meropenem (29 %), linezolid (21%)," exact="amoxicillin" post="(14%) and vancomycin (14 %). Ciprofloxacin was largely used"/>
  <result pre="(36 %), meropenem (29 %), linezolid (21%), amoxicillin (14%) and" exact="vancomycin" post="(14 %). Ciprofloxacin was largely used (57 %), mainly"/>
  <result pre="for children with severe allergic asthma. Binding to free IgE," exact="omalizumab" post="reduces cell-bound IgE, down-regulates IgE receptors and prevents the"/>
  <result pre="release of pro-inflammatory mediators [2]. The efficacy and safety of" exact="omalizumab" post="have been established by several randomized controlled trials specifically"/>
  <result pre="randomized controlled trials specifically conducted in pediatric patients [3]. Overall," exact="omalizumab" post="was effective in reducing the rate of asthma exacerbations,"/>
  <result pre="subjects [3]. A large amount of safety data showed that" exact="omalizumab" post="is generally well-tolerated. The main side effects reported were"/>
  <result pre="support an increased risk of malignancy in patients treated with" exact="omalizumab" post="[3]. Other biologic therapies have provided new evidence of"/>
  <result pre="R, Marseglia A, Ciprandi G. The discovery and development of" exact="omalizumab" post="for the treatment of asthma. Expert Opin Drug Discov."/>
  <result pre="first line-steroid-sparing agent, whilst anti-tumor necrosis factor-α (anti-TNFα) agents, as" exact="adalimumab" post="and infliximab are currently used as second line agents,"/>
  <result pre="agent, whilst anti-tumor necrosis factor-α (anti-TNFα) agents, as adalimumab and" exact="infliximab" post="are currently used as second line agents, in case"/>
  <result pre="has been shown a higher probability of maintaining remission on" exact="adalimumab" post="than infliximab during the time of treatment, and a"/>
  <result pre="shown a higher probability of maintaining remission on adalimumab than" exact="infliximab" post="during the time of treatment, and a better efficacy"/>
  <result pre="the first anti-TNFα agent failed, there is evidence that increasing" exact="adalimumab" post="dose and/or administration or switching to a second anti-TNFα"/>
  <result pre="emerging treatment for uveitis and cystoid macular oedema. Rituximab and" exact="canakinumab" post="are progressively showing an emerging role in chronic resistant"/>
  <result pre="Emmi G, et al. Safety profile of the interleukin-1 inhibitors" exact="anakinra" post="and canakinumab in real-life clinical practice: a nationwide multicenter"/>
  <result pre="et al. Safety profile of the interleukin-1 inhibitors anakinra and" exact="canakinumab" post="in real-life clinical practice: a nationwide multicenter retrospective observational"/>
  <result pre="Corsello G. Early treatment of systemic juvenile idiopathic arthritis with" exact="canakinumab" post="and complete remission after 2 years of treatment suspension:"/>
  <result pre="In the last years increasing evidence supports the use of" exact="anakinra" post="in the treatment of MAS associated with sJIA. Recently,"/>
  <result pre="in the management of rheumatic diseases. Since the introduction of" exact="methotrexate" post="in the early ‘90s, the treatment of JIA was"/>
  <result pre="assessed at the arrival, at 1 and 2 hours after" exact="paracetamol" post="(20 mg/kg orally or 15 mg/kg IV) or ibuprofen"/>
  <result pre="after paracetamol (20 mg/kg orally or 15 mg/kg IV) or" exact="ibuprofen" post="(10mg/kg orally) administration according to OMS guidelines and pain"/>
  <result pre="effective in TTH at 2 hours after administration compared to" exact="paracetamol" post="(OR 6.00). Paracetamol administered both orally (OR 2.00) and"/>
  <result pre="IV (OR 2.50) is more effective in mixed headaches than" exact="ibuprofen" post="(OR 1.75). Ibuprofen (OR 5.50) and paracetamol administered IV"/>
  <result pre="mixed headaches than ibuprofen (OR 1.75). Ibuprofen (OR 5.50) and" exact="paracetamol" post="administered IV (OR 5.50) are more effective than paracetamol"/>
  <result pre="and paracetamol administered IV (OR 5.50) are more effective than" exact="paracetamol" post="administered orally (OR 1.50). Conclusion It may need easier"/>
  <result pre="Ibuprofen maybe more effective in the migraine and TTH than" exact="paracetamol" post="administered orally, but it needs more studies to confirm"/>
  <result pre="in 6 out of 56 emergency departments in Lombardy region" exact="amoxicillin" post="was prescribed to more than 50% of children treated"/>
 </snippets>
</snippetsTree>
